News from janssen research A wide array of domestic and global news stories; news topics include politics / government, business, technology, religion, sports/entertainment, science/nature, and health/lifestyle. Articles that appear in this section may be written in English or other languages, as well.

Sep 28, 2014, 07:00 ET

ZYTIGA® Plus Prednisone Demonstrates Statistically Significant Overall Survival After 49-Month Follow-Up Analysis in Chemotherapy-Naive Men with Metastatic Castration-Resistant Prostate Cancer

A final analysis of the Phase 3 COU-AA-302 trial presented today at the European Society for Medical Oncology (ESMO) 2014 Congress in Madrid, Spain...

Aug 29, 2014, 10:10 ET

Janssen Expands EXPLORER Global Cardiovascular Research Program to Evaluate the Role of XARELTO® in Addressing Critical Medical Needs

 Janssen Research & Development, LLC (Janssen) and its development partner, Bayer HealthCare, announced today the expansion of the EXPLORER...

Aug 25, 2014, 08:00 ET

Data on XARELTO® at ESC Congress 2014 Hot Line Session Premieres First Prospective Study of a Factor Xa Inhibitor in Elective Cardioversion

 Janssen Research & Development, LLC (Janssen) announced today that results from the Phase 3b exploratory X-VeRT study, investigating the...

Aug 05, 2014, 09:00 ET

Janssen Launches Online Healthy Minds Video Series

Janssen Research & Development, LLC, today launched the first in a series of online videos addressing key mental health topics and treatments...

Jun 16, 2014, 17:00 ET

New Long-Term Data Show INVOKANA® (canagliflozin) Lowers Blood Glucose in Older Patients with Type 2 Diabetes Inadequately Controlled on Other Therapies

 Janssen Research & Development, LLC (Janssen) today announced new results from a 104-week Phase 3 clinical study evaluating the long-term...

Jun 10, 2014, 08:56 ET

Janssen to Present Latest Data for Type 2 Diabetes Treatment INVOKANA® (canagliflozin) at American Diabetes Association 74th Scientific Sessions®

 Janssen Research & Development, LLC (Janssen) announced today that 15 presentations on INVOKANA® (canagliflozin) will be made at the...

May 14, 2014, 17:12 ET

Janssen to Showcase Growing Body of Data at 2014 American Society of Clinical Oncology (ASCO) Annual Meeting

Janssen Research & Development, LLC (Janssen) announced data related to seven compounds have been selected for presentation at the 50th Annual...

May 14, 2014, 08:00 ET
May 07, 2014, 07:45 ET
May 05, 2014, 08:00 ET

Innovative Public-Private Consortium Established To Define The Triggers Of Inflammatory Bowel Disease

 Janssen Research & Development, LLC (Janssen) announced today the establishment of a Cooperative Research and Development Agreement...

Apr 08, 2014, 08:06 ET

Supplemental New Drug Application for IMBRUVICA™ (ibrutinib) Submitted to the U.S. FDA

 Janssen Research & Development, LLC ("Janssen") today announced the submission of a supplemental New Drug Application (sNDA) for...

Apr 01, 2014, 07:45 ET

Janssen Submits New Drug Application to U.S. FDA for a Fixed-Dose Combination Tablet of HIV-1 Medicine Darunavir with Cobicistat as Part of Combination HIV Therapy

Janssen Research & Development, LLC (Janssen), today announced it has submitted a New Drug Application (NDA) to the U.S. Food and Drug...

Mar 31, 2014, 08:00 ET

Janssen Expands the EXPLORER Global Cardiovascular Research Program with Three New Studies Evaluating XARELTO® in Patients at Risk for Venous Thromboembolism

Janssen Research & Development, LLC (Janssen) announced today it is adding three new clinical trials to its EXPLORER global cardiovascular...

Mar 24, 2014, 08:13 ET

Anti-Interleukin-23 Monoclonal Antibody Guselkumab Shows Significant Efficacy in Treatment Of Moderate To Severe Plaque Psoriasis

 New findings presented for the first time at the 2014 Annual Meeting of the American Academy of Dermatology (AAD) showed up to 86 percent of...

Mar 20, 2014, 08:00 ET

Janssen Investigational Treatment for Schizophrenia Shows Positive Efficacy, Delays Relapse

 Janssen Research & Development, LLC announced today that following an Independent Data Monitoring Committee (IDMC) recommendation based on...

Feb 21, 2014, 08:00 ET

Janssen Initiates CREDENCE Study in Patients with Type 2 Diabetes and Diabetic Nephropathy

Janssen Research & Development, LLC (Janssen) today announced the initiation of CREDENCE (Canagliflozin and Renal Events in Diabetes with...

Feb 14, 2014, 08:00 ET

FDA Issues Complete Response Letters for Use of XARELTO® (rivaroxaban) to Reduce the Risk of Secondary Cardiovascular Events and Stent Thrombosis in Patients with Acute Coronary Syndrome

 Janssen Research & Development, LLC (Janssen) announced today the U.S. Food and Drug Administration (FDA) issued complete response letters...

Jan 16, 2014, 16:46 ET

FDA Advisory Committee Recommends Against Approval of the Use of Oral Anticoagulant XARELTO® to Reduce the Risk of Thrombotic Cardiovascular Events in Patients with Acute Coronary Syndrome

 Janssen Research & Development, LLC (Janssen) announced today the U.S. Food and Drug Administration's (FDA) Cardiovascular and Renal...

Jan 07, 2014, 09:41 ET

Independent Data Monitoring Committee Recommends Early Stopping of Phase 3 Study of Ibrutinib in Relapsed/Refractory CLL/SLL Patients Based on a Planned Interim Analysis

 Janssen Research & Development, LLC today announced the early stopping of PCYC-1112-CA, the Phase 3 study of IMBRUVICA™ (ibrutinib)...

Dec 12, 2013, 17:26 ET

FDA Issues Complete Response Letter for Canagliflozin/Metformin Fixed-Dose Combination Therapy for Type 2 Diabetes

 Janssen Research & Development, LLC (Janssen) today announced it has received from the U.S. Food and Drug Administration (FDA) a complete...